Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 681 for “"PD-L1"”.
-
PD-1/PD-L1 immunotherapy blockade in solid tumors: role of PD-1/PD-L1 in cancer disease progression
… concept behind cancer and focuses on the use of PD-1 in tumors as a way of immune evasion as well as the use of PD-1/PD-L1 blockade as an innovative target for immunotherapy. Cancer arises from mutagenic events resulting in the presence of abnormal cells and uncontrollable cell proliferation. It …
-
PD-L1 Nano-Eraser: A Novel Intracellular PD-L1 Degradation Approach and Its Application in Cancer and Alzheimer’s Disease Therapy
… application of anti-Programmed Death Ligand 1 (PD-L1) antibody (aPDL1) in cancer treatment and Alzheimer’s disease therapy by leveraging the Trim-Away pathway. aPDL1-based Trim-Away involves tagging target PD-L1 with TRIM21, and followed by proteasome-mediated degradation of PD-L1, leading to …
-
PD-L1 expression by tumor macrophages: regulation and signaling
To view the abstract, please see the full text of the document.
-
Regulation of the immune checkpoint PD-L1 by microRNAs
… responses and inflammation. The expression of PD-L1 protein is found on some normal and cancer cells and contributes to suppression of T cell activity by acting as a brake on the immune response. Previously, it has been shown that posttranscriptional mechanisms regulate PD-L1 levels in cancer, …
-
Tumour copper levels regulate PD-L1 driven immune evasion
… over-expression of Programmed Death Ligand 1 (PD-L1). The immune checkpoint protein Programmed Death receptor 1 (PD-1) expressed by lymphocytes negatively regulates T-cells effector functions against target cells, including tumour cells. Several therapeutic monoclonal antibodies targeting …
-
A THERANOSTIC APPROACH TOWARDS PROGRAMMED DEATH-LIGAND 1 (PD-L1)
… and eliminate cancer. Programmed death-ligand 1(PD-L1) is a crucial immune checkpoint marker that inhibits anti-tumor response by engaging with its ligand, PD-1 on cytotoxic T cells. Targeting PD-1/PD-L1 axis remains avidly explored avenue clinically, however, a substantial subset of patients …
-
Lipid-based microbubbles for enhanced delivery of anti PD-l1
… conjugating immunotherapeutic drugs, i.e. anti PD-L1, onto microbubbles via chemical conjugation or physical methods. However, clinical translation requires an accurate characterisation method for antibody loading, as well as the establishment of point-of-care manufacturing processes for …
-
Tumor Intrinsic Consequences of Acquired Resistance to PD-L1 Inhibition
Programmed death ligand 1 (PD-L1) expressed on tumor cells can bind to its receptor PD-1 on T cells to effectively block tumor suppressing immunity. Immune checkpoint inhibitors (ICIs) include drugs that target PD-L1, several of which are clinically approved to treat late- and early-stage cancers. …
-
Entwicklung von niedermolekularen PD-L1- Radioliganden für die PET-Bildgebung
Der Programmed Death-Ligand 1 (PD-L1) wird von verschiedenen Tumorentitäten überexprimiert und hemmt durch die Bindung an das auf T-Zellen vorkommende Programmed Cell Death Protein (PD-1) die Immunantwort. Immuncheckpoint-Inhibitoren sind in der Lage, diese Blockade aufzubrechen und die …
-
THE ROLE OF IMMUNE CHECKPOINT PD-L1 IN HOMEOSTASIS AND INFLAMMATION
… immune checkpoint, programmed death ligand 1 (PD-L1), in arthritis through the development of an immune checkpoint inhibitor-induced inflammatory arthritis mouse model (ICI-IA) by blocking PD-L1 during collagen induced arthritis (CIA). The joints of ICI-IA mice showed severe arthritis with …
-
Development of Gold Nanoparticles for Targeting PD-L1-Presenting Breast Cancers
… programmed cell death protein ligand 1 (PD-L1) presenting cancer cells with gold nanoparticles (AuNP). Initially, small molecules, described as antagonists for the PD-1/PD-L1 interaction, were considered as promising targeting agents for the gold platform. The competitive binding profiles …
-
Inhibitors of the PD1/PD-L1 interaction: missteps, mechanisms and mysteries
… is by expressing programmed death ligand 1 (PD-L1). PD-L1 binds to its receptor programmed death 1 (PD1) on T cells, inhibiting T cell responsiveness to antigenic stimuli. Blockade of the PD1/PD-L1 pathway removes this negative signal and restores anti-tumour immunity. While this blockade of …
-
Parp Inhibitor Upregulates Pd-L1 Expression and Enhances Cancer-Associated Immunosuppression
… for therapeutic antibodies that block CTLA4, PD-1 and PD-L1, immune checkpoints have emerged as new targets in cancer therapy. In addition, there is accumulating evidence highlighting the role of cancer-associated immunity in patient response to cytotoxic anticancer agents. Inhibitors of poly …
-
Expression von PD-L1 und PD-1 im nicht-kleinzelligen Lungenkarzinom
… beschäftigt sich mit der Expression der Proteine PD-L1 (B7-H1,<br>CD274) und PD-1 (CD279) auf Tumorzellen und TIL des NSCLC. Tumorseitig soll PD-L1 den auf<br>infiltrierenden Lymphozyten exprimierten Rezeptor PD-1 inhibieren und dadurch zu einer Anergie<br>des Immunsystems und in Folge dessen zu …
-
Novel imaging technique to determine PD-L1 expression in breast cancer
… triple negative breast cancer when treated with PD-L1 inhibitor pembrolizumab in the neoadjuvant and adjuvant phase of treatment. However, this result was independent of PD-L1 expression of the tumor as measured by immunohistochemistry (IHC). Studies also have found that IHC measurement of PD-L1 …
-
Epigenetic and Mechanotransducive Regulation of PD-L1 Expression in Breast Cancer Cells
… TNBC patients.9,10 programmed death-ligand 1 (PD-L1) is an important immune checkpoint which overexpressed in TNBC.11 Here, epigenetic and mechanotransducive regulation of PD-L1 was examined in this study. We showed that in MDA-MB-231 cells, slicing and inhibition of MLL downregulate PD-L1 …
-
Characterizing PD-L1-Targeting Extracellular Vesicles Produced by Oncolytic Vaccinia Virus Infection
… molecules. The programmed cell death ligand 1 (PD-L1) plays a major role in this immunosuppression, and its expression is often up regulated as a result of innate and adaptive resistance mechanisms. Recent studies have discovered that the expression of PD-L1 can also extend to the nanoparticles …
-
Μελέτη της έκφρασης των PD-1/PD-L1 σε κακοήθη αιματολογικά νοσήματα
… την πρώτη ύφεση της νόσου. Η αλληλεπίδραση των PD-1/PD-L1 συγκαταλέγεται στους πιθανούς τρόπους διαφυγής των νεοπλασματικών κυττάρων από την ανοσοεπιτήρηση. Η δυσλειτουργία των Τ λεμφοκυττάρων οφείλεται στη δράση του υποδοχέα PD-1 (Programmed Death-1), ο οποίος επάγεται από τον συνδέτη PD-L1 …
Page 1 of 35